Should de-escalation of bone-targeting agents be standard of care?

被引：0
作者：
Awan, A. [1 ]
Hutton, B. [2 ]
Clemons, M. [3 ,4 ]
机构：
[1] McGill Univ, Div Med Oncol, Dept Oncol, Montreal, PQ, Canada
[2] Ottawa Hosp Res Inst, Clin Epidemiol Program, Ottawa, ON, Canada
[3] Ottawa Hosp Canc Ctr, Div Med Oncol, Ottawa, ON, Canada
[4] Ottawa Hosp Res Inst, Ottawa, ON, Canada
来源：
ANNALS OF ONCOLOGY | 2018年 / 29卷 / 05期
关键词：
BREAST-CANCER; PHASE-II; METASTASES; DENOSUMAB; EFFICACY; SAFETY; TRIAL;
D O I：
10.1093/annonc/mdy068
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1333 / 1334
页数：3
相关论文
共 28 条
  • [21] Treatment dynamics of bone-targeting agents among men with bone metastases from prostate cancer in the United States
    Butler, Anne M.
    Cetin, Karynsa
    Hernandez, Rohini K.
    Reams, B. Diane
    Overman, Robert A.
    Kim, Jung I.
    Hirsch, Bradford R.
    Abernethy, Amy P.
    Liede, Alexander
    Brookhart, M. Alan
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2018, 27 (02) : 229 - 238
  • [22] The presenting dental status of solid tumours with bone metastases requiring bone-targeting agents-part 3: prostate cancer
    Patel, Vinod
    Burns, Megan
    Patel, Sheelen
    Grossman, Sanford
    Wali, Rana
    Sassoon, Isabel
    Pintus, Elias
    Henien, Marianne
    BRITISH DENTAL JOURNAL, 2022,
  • [23] Real-world practice patterns and attitudes towards de-escalation of bone-modifying agents in patients with bone metastases from breast and prostate cancer: A physician survey
    AlZahrani, Mashari
    Clemons, Mark
    Vandermeer, Lisa
    Sienkiewicz, Marta
    Awan, Arif Ali
    Hutton, Brian
    Pond, Gregory R.
    Ng, Terry L.
    JOURNAL OF BONE ONCOLOGY, 2021, 26
  • [24] Comparative Treatment Persistence with Bone-Targeting Agents Among Asian Patients with Bone Metastases from Solid Tumors: A Multinational Retrospective Cohort Study
    Shen, Chin-Yao
    Au, Philip Chun-Ming
    Baek, Yeon-Hee
    Cheung, Ching-Lung
    Chung, Wei-Pang
    Kim, Ju Hwan
    Kleinman, Nora J.
    Lam, Tai-Chung
    Liao, Tzu-Chi
    Lin, Tzu-Chieh
    Shin, Ju-Young
    Sing, Chor-Wing
    Wong, Ian Chi Kei
    Lai, Edward Chia-Cheng
    BIODRUGS, 2022, 36 (03) : 381 - 392
  • [25] Assessing response to treatment of bone metastases from breast cancer: what should be the standard of care?
    Woolf, D. K.
    Padhani, A. R.
    Makris, A.
    ANNALS OF ONCOLOGY, 2015, 26 (06) : 1048 - 1057
  • [26] Extended, standard, or De-escalation antiplatelet therapy for patients with coronary artery disease undergoing percutaneous coronary intervention? A trial-sequential, bivariate, influential, and network meta-analysis
    Ullah, Waqas
    Zahid, Salman
    Sandhyavenu, Harigopal
    Faisaluddin, Mohammed
    Khalil, Fouad
    Pasha, Ahmad K.
    Alraies, M. Chadi
    Cuisset, Thomas
    Rao, Sunil, V
    Sabouret, Pierre
    Savage, Michael P.
    Fischman, David L.
    EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY, 2022, 8 (07) : 717 - 727
  • [27] Discordance between hormone receptor profile of primary breast cancer and metastatic bone disease: should bone marrow biopsy be considered a standard of care?
    Amir, E.
    Broom, R.
    Freedman, O.
    Ooi, W. S.
    Done, S.
    Gianfelice, D.
    Barth, D.
    Kahn, H.
    Clemons, M.
    BREAST CANCER RESEARCH, 2009, 11 : S18 - S18
  • [28] Discordance between hormone receptor profile of primary breast cancer and metastatic bone disease: should bone marrow biopsy be considered a standard of care?
    E Amir
    R Broom
    O Freedman
    WS Ooi
    S Done
    D Gianfelice
    D Barth
    H Kahn
    M Clemons
    Breast Cancer Research, 11
123